206 related articles for article (PubMed ID: 9583927)
1. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.
Jha TK; Olliaro P; Thakur CP; Kanyok TP; Singhania BL; Singh IJ; Singh NK; Akhoury S; Jha S
BMJ; 1998 Apr; 316(7139):1200-5. PubMed ID: 9583927
[TBL] [Abstract][Full Text] [Related]
2. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial.
Thakur CP; Bhowmick S; Dolfi L; Olliaro P
Trans R Soc Trop Med Hyg; 1995; 89(2):219-23. PubMed ID: 7778155
[TBL] [Abstract][Full Text] [Related]
3. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.
Thakur CP; Olliaro P; Gothoskar S; Bhowmick S; Choudhury BK; Prasad S; Kumar M; Verma BB
Trans R Soc Trop Med Hyg; 1992; 86(6):615-6. PubMed ID: 1337634
[TBL] [Abstract][Full Text] [Related]
4. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.
Chunge CN; Owate J; Pamba HO; Donno L
Trans R Soc Trop Med Hyg; 1990; 84(2):221-5. PubMed ID: 2167522
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.
Thakur CP; Kanyok TP; Pandey AK; Sinha GP; Zaniewski AE; Houlihan HH; Olliaro P
Trans R Soc Trop Med Hyg; 2000; 94(4):429-31. PubMed ID: 11127250
[TBL] [Abstract][Full Text] [Related]
6. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis.
Hepburn NC; Tidman MJ; Hunter JA
Trans R Soc Trop Med Hyg; 1994; 88(6):700-3. PubMed ID: 7886779
[TBL] [Abstract][Full Text] [Related]
7. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.
Seaman J; Pryce D; Sondorp HE; Moody A; Bryceson AD; Davidson RN
J Infect Dis; 1993 Sep; 168(3):715-20. PubMed ID: 8394861
[TBL] [Abstract][Full Text] [Related]
8. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
[TBL] [Abstract][Full Text] [Related]
9. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.
Thakur CP; Sinha GP; Pandey AK; Kumar N; Kumar P; Hassan SM; Narain S; Roy RK
Ann Trop Med Parasitol; 1998 Jul; 92(5):561-9. PubMed ID: 9797829
[TBL] [Abstract][Full Text] [Related]
10. Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study.
Thakur CP; Kumar M; Kumar P; Mishra BN; Pandey AK
Br Med J (Clin Res Ed); 1988 Jun; 296(6636):1557-61. PubMed ID: 2840172
[TBL] [Abstract][Full Text] [Related]
11. Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis.
Poli A; Sozzi S; Guidi G; Bandinelli P; Mancianti F
Vet Parasitol; 1997 Aug; 71(4):263-71. PubMed ID: 9299695
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
Tamiru A; Mohammed R; Atnafu S; Medhin G; Hailu A
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009713. PubMed ID: 34464401
[TBL] [Abstract][Full Text] [Related]
13. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
Musa A; Khalil E; Hailu A; Olobo J; Balasegaram M; Omollo R; Edwards T; Rashid J; Mbui J; Musa B; Abuzaid AA; Ahmed O; Fadlalla A; El-Hassan A; Mueller M; Mucee G; Njoroge S; Manduku V; Mutuma G; Apadet L; Lodenyo H; Mutea D; Kirigi G; Yifru S; Mengistu G; Hurissa Z; Hailu W; Weldegebreal T; Tafes H; Mekonnen Y; Makonnen E; Ndegwa S; Sagaki P; Kimutai R; Kesusu J; Owiti R; Ellis S; Wasunna M
PLoS Negl Trop Dis; 2012; 6(6):e1674. PubMed ID: 22724029
[TBL] [Abstract][Full Text] [Related]
14. Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.
Das VN; Ranjan A; Bimal S; Siddique NA; Pandey K; Kumar N; Verma N; Singh VP; Sinha PK; Bhattacharya SK
Natl Med J India; 2005; 18(3):131-3. PubMed ID: 16130613
[TBL] [Abstract][Full Text] [Related]
15. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica.
Teklemariam S; Hiwot AG; Frommel D; Miko TL; Ganlov G; Bryceson A
Trans R Soc Trop Med Hyg; 1994; 88(3):334-9. PubMed ID: 7974682
[TBL] [Abstract][Full Text] [Related]
16. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar.
Mishra M; Biswas UK; Jha AM; Khan AB
Lancet; 1994 Dec; 344(8937):1599-600. PubMed ID: 7983993
[TBL] [Abstract][Full Text] [Related]
18. Antileishmanial efficacy and tolerability of combined treatment with non-ionic surfactant vesicle formulations of sodium stibogluconate and paromomycin in dogs.
Miret JA; Moreno J; Nieto J; Carter KC; Mullen AB; Ambros L; Rodríguez C; San Andrés MI; González F
Exp Parasitol; 2021 Jan; 220():108033. PubMed ID: 33166530
[TBL] [Abstract][Full Text] [Related]
19. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
[TBL] [Abstract][Full Text] [Related]
20. Experience with amphotericin B in sodium stibogluconate--unresponsive cases of visceral Leishmaniasis in north Bihar.
Giri OP; Singh AN
J Assoc Physicians India; 1994 Sep; 42(9):690-1. PubMed ID: 7883660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
